Recent studies have shown that these drugs also could be used in patients to treat heart failure or to slow the progression of renal failure, irrespective of whether the patients have diabetes or not. In this review, we discuss the clinical trial evidence for the use of SGLT2 inhibitors for...
as various classes of drugs antagonizing the neuro-hormonal systems, successfully used for the management of HF with reduced EF (HFrEF), did not achieve statistically significant benefits, though in many studies their bene...
Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in patients with heart failure and preserved ejection fraction (HFpEF). In the midst of the Coronavirus Disease 2019 pandemi...
第二步 ,评估患者 中国心力衰竭中心联盟专家委员会.心力衰竭 SGLT2抑制剂临床应用的中国专家共识 ·602· ExpertCommitteeofChineseHeartFailureCenterAlliance.ConsensusofChineseexpertsonthe ... 对血压和肾功能 的耐受性,在第一步的 1~2 周内 添加血管紧张素受 体脑啡肽酶抑制剂(angiotensin recpetorneprilysin...
SGLT-2抑制剂可是在雷帕霉素、亚甲蓝和二甲双胍等药物中杀出重围，它在实验和临床应用中展现出巨大抗衰潜能，一举夺魁。然而，这位延寿抗衰的新科状元似乎因“私生活”过于低调，并不为大众所熟知，不过没关系，小编已打点好门路，将带您共同一睹其英姿。知其然，要知其所以然 ——SGLT-2和SGLT-2抑制剂 民以...
Heart failure (HF) continues to be a serious public health challenge despite significant advancements in therapeutics and is often complicated by multiple other comorbidities. Of particular concern is type 2 diabetes mellitus (T2DM) which not only amplifies the risk, but also limits the treatment opt...
Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults Ashkan Hashemi Min Ji Kwak Parag Goyal Drugs & Aging (2025) Effect of SGLT-2 inhibitors on acute kidney injury in patients with heart failure: a systematic review and meta-analysis Xianghong Wang...
This article reviews the electrophysiological basis of the antiarrhythmic effects of this type of drugs from the perspective of ion channels参考文献/References: [1] Fernandes GC,Fernandes A,Cardoso R,et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with ...
Although anti- heart failure drugs have been updated continuously in recent years, heart failure is still incurable. Therefore, it is urgent to find new therapeutic targets to improve the prognosis of HF patients. Empagliflozin is a sodium-glucose co-transporter 2(SGLT2) inhibitor. A large ...
The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in patients who are hospitalized for acute heart failure is unk...